- Home
- AKBA
as of 02-09-2026 12:17pm EST
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 729.1M | IPO Year: | 2014 |
| Target Price: | $5.92 | AVG Volume (30 days): | 3.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $4.08 | Next Earning Date: | 03-12-2026 |
| Revenue: | $225,071,000 | Revenue Growth: | 32.49% |
| Revenue Growth (this year): | 52.41% | Revenue Growth (next year): | 21.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 32.2M | FCF Growth: | N/A |
AI-Powered AKBA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Akebia Therapeutics Inc. (AKBA)
SVP, CFO, CBO & Treasurer
Avg Cost/Share
$1.39
Shares
34,951
Total Value
$48,581.89
Owned After
672,635
SEC Form 4
CEO and President
Avg Cost/Share
$1.39
Shares
341,305
Total Value
$474,413.95
Owned After
3,297,794
SVP, Chief Medical Officer
Avg Cost/Share
$1.39
Shares
67,658
Total Value
$94,044.62
Owned After
969,133
SVP, Chief Accounting Officer
Avg Cost/Share
$1.39
Shares
49,524
Total Value
$68,838.36
Owned After
312,772
Chief Commercial Officer
Avg Cost/Share
$1.39
Shares
84,829
Total Value
$117,912.31
Owned After
561,750
SVP, Chief Legal Officer
Avg Cost/Share
$1.39
Shares
69,772
Total Value
$96,983.08
Owned After
588,378
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Ostrowski Erik | AKBA | SVP, CFO, CBO & Treasurer | Feb 2, 2026 | Sell | $1.39 | 34,951 | $48,581.89 | 672,635 | |
| Butler John P. | AKBA | CEO and President | Feb 2, 2026 | Sell | $1.39 | 341,305 | $474,413.95 | 3,297,794 | |
| Burke Steven Keith | AKBA | SVP, Chief Medical Officer | Feb 2, 2026 | Sell | $1.39 | 67,658 | $94,044.62 | 969,133 | |
| Malabre Richard C | AKBA | SVP, Chief Accounting Officer | Feb 2, 2026 | Sell | $1.39 | 49,524 | $68,838.36 | 312,772 | |
| Grund Nicholas | AKBA | Chief Commercial Officer | Feb 2, 2026 | Sell | $1.39 | 84,829 | $117,912.31 | 561,750 | |
| Rucci Carolyn M. | AKBA | SVP, Chief Legal Officer | Feb 2, 2026 | Sell | $1.39 | 69,772 | $96,983.08 | 588,378 |
Compare AKBA vs Leading Stocks
See how AKBA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AKBA Akebia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.